Company Overview
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Why Investors Should Care
Revenue has grown at a 70.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $19.39M (+68.0% YoY); net profit $-6.13M.
- Trailing 12 Months Year-on-year growth — revenue -96.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 70.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 70.92% |
| 1 Year: | -96.60% |
Stock Price Performance
| 1 Year: | +348.85% |
| 6 Months: | -18.38% |
| 3 Months: | -13.29% |
| 1 Month: | -21.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 70.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLGL Sol-Gel Technologies Ltd. PHARMA | 69.37 | -12.34 | $227.12M | 0.00% | -31.74% | -40.85% | 70.92% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.03M | 17.26M | 400.00K | 696.00K | 108.00K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 10.10M | 6.03M | 6.69M | 4.11M | 3.96M |
| Operating Income | -9.07M | 11.23M | -6.29M | -3.41M | -3.85M |
| EBITDA | -9.07M | 11.23M | -6.29M | -3.41M | -3.85M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -8.81M | 11.61M | -5.94M | -2.99M | -3.73M |
| Tax Provision | - | - | - | - | - |
| Net Income | -8.81M | 11.61M | -5.94M | -2.99M | -3.73M |
| Diluted EPS | -3.20 | 4.17 | -2.13 | - | -1.31 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.88M | 1.55M | 11.54M | 19.39M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 20.13M | 30.86M | 23.55M | 26.93M |
| Operating Income | - | -16.24M | -29.30M | -12.01M | -7.54M |
| EBITDA | - | -15.68M | -28.96M | -11.78M | -7.43M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | -14.92M | -27.24M | -10.58M | -6.13M |
| Tax Provision | 0 | - | - | - | - |
| Net Income | - | -14.92M | -27.24M | -10.58M | -6.13M |
| Diluted EPS | - | -6.50 | -10.01 | -3.79 | -2.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 46.63M | 45.29M | 35.85M | 29.92M |
| Current Assets | - | 43.05M | 41.17M | 31.30M | 26.97M |
| Cash & Equivalents | - | 12.45M | 7.51M | 19.49M | 11.03M |
| Inventory | - | - | - | - | - |
| Receivables | - | 62.00K | 377.00K | 3.60M | 1.97M |
| Total Liabilities | - | 4.42M | 6.64M | 7.00M | 7.11M |
| Current Liabilities | - | 3.33M | 4.52M | 5.29M | 6.17M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 772.00K | 1.65M | 1.31M | 991.00K |
| Total Equity | - | 42.21M | 38.64M | 28.85M | 22.81M |
| Shares Outstanding | - | 2.31M | 2.79M | 2.79M | 2.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.48M | -17.73M | -13.89M | 322.00K |
| Investing Cash Flow | - | 1.70M | -9.74M | 26.69M | -8.58M |
| Financing Cash Flow | - | 15.00K | 21.81M | 0 | 6.00K |
| Capital Expenditure | - | -171.00K | -134.00K | -2.00K | -47.00K |
| Free Cash Flow | - | -9.65M | -17.86M | -13.89M | 275.00K |
| Net Change in Cash | - | -7.77M | -5.66M | 12.80M | -8.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -418.3% | -1,885.8% | -104.1% | -38.9% |
| Net Margin % | - | -384.3% | -1,752.8% | -91.7% | -31.6% |
| ROE % | - | -35.4% | -70.5% | -36.7% | -26.9% |
| ROCE % | - | -37.5% | -71.9% | -39.3% | -31.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 17.79% | 500.00K | $30.00M |
| 2 | Great Point Partners LLC | 9.76% | 274.36K | $16.46M |
| 3 | Phoenix Financial Ltd. | 5.20% | 146.15K | $8.77M |
| 4 | Trails Edge Capital Partners, LP | 4.96% | 139.44K | $8.37M |
| 5 | Affinity Asset Advisors, Llc | 3.02% | 84.90K | $5.09M |
| 6 | Squadron Capital Management LLC | 1.85% | 52.00K | $3.12M |
| 7 | Citadel Advisors Llc | 1.16% | 32.56K | $1.95M |
| 8 | Gilder Gagnon Howe & Co LLC | 0.80% | 22.50K | $1.35M |
| 9 | Stonepine Capital Management, LLC | 0.51% | 14.47K | $868.14K |
| 10 | Yelin Lapidot Holdings Management Ltd. | 0.37% | 10.38K | $623.04K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLGL
Discipline and Rules-Based Execution in SLGL Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNckdSSW9KTER5VDlUUlY3UVNXcS1adDdCWFNVTGdUQzJvR1paaUJOQkF3MllJaURDeEhjTHdWSlpHMWpPWGt1ZE1KTkZFNjBXX3B2c1dVN24xTGxNaGsyY2JVYndpNE9JeHMzY253VHk0VUFTR05YVVphdlg4RnE2UFZ0dldzOGFpeFBVYn…
$SLGL stock is up 15% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNNnk4ZVV4TUF5M3ZwN1Bac29HcGczQi0tdm8wYTZmeE53Z3ZSdnpJUGh0TXcycWpiM2F6dFJiYUVseU1XcUkybEt1TExQcVUyUExmeW82UURuLU4xa0ZUTGZ4bTJuWHcxcGZQSlBVSGQ5OTB3WUMzeVlxZGZ2T18wcC1YUzVHUU1ycGNEMX…
Sol Gel Technologies Ltd (NASDAQ: SLGL) Stock Price, News & Analysis - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE84RVhLNVlaMmowdWFpRnlqT2k0aWlPQ3dkRHNxa2l1dzBSTnVUcW00dGRiRTg1RERWdHNxNkVpaDNaTFBJQkVoSnlKMndCTFlp?oc=5" target="_blank">Sol Gel Technologies Ltd (NASDAQ: SLGL) Stock Price, News &…
SLGL - Sol-Gel Technologies Ltd Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE4zXzJDVW9fQ1dLUmZqSFo4djlsVzd3UlVURUJubUJEdXZrYW9WYXItNmRlTFhuUEdXZGxsU3E5NHNocDZtcHc?oc=5" target="_blank">SLGL - Sol-Gel Technologies Ltd Stock Price and Quote</a> <fo…
Sol-Gel Technologies (NASDAQ: SLGL) sees cash runway into Q1 2028 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOSndsVmdvM0dlR2lmUDlLNEdEaTg1OWhudXJsVDJNOFZFVFpDckJJcWpWWllodUFNeGNxakVCNVI4N3BHM0hQbm1QOE1lbF9ReHFTcTBTS0E0M1pYNkZhWjJEU0VnMnZHRXJHZ2JkYzZhQUZlM3QyQXFnQUZrdUk5Sm9qWkxicHlmeEhGd0…
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOTW9aSUlYc29IU1FPc0o1eHpCTDJNYUlzTXlDX0Joc3RaVjNzY1poU2trUU1mb0M3QUhOaVRkQ0tHMEZRY3owRE1GRWV6UzFlQXhMeGNaWU9YMVN5ZDU1a01VbmtLdmptRVhzd09JSzdBQ3F6aHhGZDcyTnJDY1FXTm1nMGpLWHNmS19EeH…
SLGL — Frequently Asked Questions
What is the current share price of Sol-Gel Technologies Ltd. (SLGL)?
As of 2026-09-19 21:16 PDT, Sol-Gel Technologies Ltd. (SLGL) trades at $69.37 on NasdaqCM. Its 52-week range is $15.25 to $97.97.
What is the market capitalisation of SLGL?
Sol-Gel Technologies Ltd. (SLGL) has a market capitalisation of $227.12M on NasdaqCM.
What is the P/E ratio of SLGL?
SLGL trades at a trailing price-to-earnings (P/E) ratio of -12.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.08.
What is the return on equity (ROE) of SLGL?
SLGL has a return on equity (ROE) of -40.85%. Its return on capital employed (ROCE) is -31.74%.
Is SLGL a good stock to buy?
This page provides a data-driven analysis of Sol-Gel Technologies Ltd. (SLGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.